🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis

Clinical Infectious Diseases(2024)10.1093/cid/ciae119Source: DataRank Database

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0.306. It has been cited 6 times, with 6 citing works in its 1-hop citation network.

N/A

0.306DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access6 citations · 6 citing works in its network

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02410772

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (35 grants)Impact (FWCI 1.83)OA: hybridTopics (61)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 95%Citation Network 5%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

0.0140

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 6 citers.

Characterization of the complex TB pharmacogenomic landscape in Africa using bioinformatic tools
Briefings in Bioinformatics20251 citations67 referencesContributes 0.010
GEODE: an in silico tool that translates in vitro to in vivo predictions of tuberculosis antibiotic combination efficacy
Frontiers in Pharmacology20251 citations114 referencesContributes 0.006
Advancing Pediatric Drug Safety: The Potential of Physiologically Based Pharmacokinetic Modeling
Drug Metabolism and Bioanalysis Letters20250 citations232 referencesContributes 0.000
Rifampin Exposure in Pregnant and Nonpregnant Women With Tuberculosis in India
The Journal of Infectious Diseases20250 citations11 referencesContributes 0.000
Machine learning-guided clinical pharmacist interventions improve treatment outcomes in tuberculosis patients: a precision medicine approach
Frontiers in Artificial Intelligence20250 citations18 referencesContributes 0.000

Authors (21)

Ava Y Xu ORCID,Gustavo E. Velásquez ORCID,Nan Zhang ORCID,Vincent Chang ORCID,Ekaterina V. Kurbatova ORCID

Live enrichment

PubMed:38462673 OpenAlex:https://openalex.org/W4392637042

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32582

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32593

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32594

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32589

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32597

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 200-2009-32598

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06702

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06701

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06703

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06222

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06225

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Grant: 75D30119C06010

National Institutes of Health

Grant: UM1 AI068634

National Institutes of Health

Grant: UM1 AI068636

National Institutes of Health

Grant: UM1 AI106701

Roche

Grant: K08 AI141740

USAID

Grant: 7200AA22CA00005

Médecins Sans Frontières

Grant: SPHQ15-LOA-045

Médecins Sans Frontières

Grant: K24 AI150349

Médecins Sans Frontières

Grant: R01 Al126788

NIAID NIH HHS

Grant: R01 AI126788

NIAID NIH HHS

Grant: UM1 AI069496

NIAID NIH HHS

Grant: R01 AI135124

National Institutes of Health

Grant: 5K08AI141740-03

Safety and tolerability of new and repurposed drugs for MDR-TB treatment

National Institutes of Health

Grant: 5K24AI150349-05

Mentoring Investigators in HIV and Tuberculosis Therapeutics Research

National Institutes of Health

Grant: 5R01AA007200-02

ENHANCED LONG-TERM BENEFITS FROM ALCOHOL TREATMENT

National Institutes of Health

Grant: 1R01AI126788-01

Novel Biomarkers to Shorten TB Treatment

Genentech

UCSF

National Institute of Allergy and Infectious Diseases

Sanofi

Sanofi

National Institute of Allergy and Infectious Diseases

Genentech

UCSF

FWCI

1.83

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae119/56919199/ciae119.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae119/56919199/ciae119.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae119/57038845/ciae119.pdf

publisherhttps://academic.oup.com/cid/article-pdf/78/6/1680/58211961/ciae119.pdf

journalhttps://doi.org/10.1093/cid/ciae119

Fields of Study

Tuberculosis Research and EpidemiologyMalaria Research and ControlAntibiotics Pharmacokinetics and Efficacy0301 basic medicine03 medical and health sciences0302 clinical medicineRifampinHumansMaleAdultFemaleMiddle AgedTuberculosisYoung AdultAntitubercular AgentsTreatment OutcomeAdolescentDose-Response Relationship, DrugAged

MeSH Terms

AdolescentAdultAgedAntitubercular AgentsDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedRifampinTuberculosisTreatment OutcomeYoung Adult

Keywords

RifampicinDosingMedicineRegimenAdverse effectTuberculosisPharmacokineticsPharmacodynamicsPharmacologyPopulationInternal medicineEnvironmental healthPathologyPopulation PharmacokineticsFlat-dosingWeight-banded DosingMaleAdultAdolescentDose-Response Relationship, DrugAntitubercular AgentsMiddle AgedYoung AdultTreatment OutcomeMajor ArticleHumansFemaleRifampinAged

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (1)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

N/A

1.4DataRank · unranked

Journal for ImmunoTherapy of Cancer(2021)

co-cited

10.1136/jitc-2020-002100